腹主动脉瘤腔内修复术后II型内漏的意义与晚期结局
单中心回顾性研究纳入2010年1月至2022年6月因退行性肾下腹主动脉瘤行EVAR且术中无I/III型内漏的803例患者,按II型内漏状态分组。中位随访5年,10年时持续/晚期II型内漏组免于瘤囊增大和动脉瘤相关再干预率更低,总生存无差异。作者认为对无I/III型内漏者保守处理可能合适。
要点
- 803例EVAR患者中约半数出现持续或晚期II型内漏。
- 持续/晚期II型内漏与10年免于瘤囊增大和再干预率降低相关。
- 两组10年总生存、破裂率和切除率无显著差异。
核心结论
- 约半数肾下EVAR患者出现持续/晚期II型内漏,与瘤囊增大和再干预风险升高相关。
- 10年时总生存或动脉瘤破裂风险按II型内漏状态或是否干预无差异。
- 作者认为对无I/III型内漏的大多数患者,保守处理II型内漏可能合适。
研究设计与样本
- 单中心回顾性研究,纳入2010年1月至2022年6月因退行性肾下腹主动脉瘤行EVAR且术中无I型或III型内漏的患者803例。
- 按II型内漏状态分组:第1组为从未检出或短暂性II型内漏(418例,52%),第2组为持续性或晚期II型内漏(385例)。
- 采用时间依赖方法进行时间-事件分析,主要结局为免于瘤囊增大、动脉瘤相关再干预和总生存。
主要发现
- 第1组418例(52%)中85%无II型内漏、15%为短暂性;第2组385例中23%为持续性、77%为新发II型内漏。
- 第1组吸烟(88% vs 83%;P < .001)、慢性阻塞性肺疾病(33% vs 25%;P = .008)、慢性肾脏病(13% vs 8%;P = .021)患病率及平均SVS评分(7 vs 6分;P = .049)高于第2组。
- 两组动脉瘤直径或形态无差异,全队列平均随访5年。
- 第2组58例(15%)接受II型内漏治疗,最常见为经动脉栓塞。
- EVAR后10年,第2组免于瘤囊增大(P < .001)和动脉瘤相关再干预(P < .001)率更低,总生存相当(P = .42)。
关键数值与推荐
- 随访期间第2组检出更多I型内漏(6例[1%] vs 20例[5%];P = .004),其中15例(75%)在II型内漏后中位3年检出。
- 两组切除率(0.7% vs 2.1%;P = .130)和动脉瘤破裂率(0.5% vs 1.3%;P = .269)无差异。
临床怎么用
- 作者认为对无I型或III型内漏的大多数患者,保守处理II型内漏可能合适。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type II endoleaks (T2ELs) are the most common cause of reintervention after endovascular aneurysm repair (EVAR). Although most resolve spontaneously, the long-term implications of T2ELs remain elusive. We aim to evaluate the impact of persistent and late T2ELs on clinical outcomes after EVAR. METHODS: This was a single-institution retrospective review of patients who underwent EVAR for degenerative infrarenal abdominal aortic aneurysm between January 2010 and June 2022 with no type I (T1EL) or III (T3EL) endoleak seen at EVAR completion. Patients were categorized based on T2EL status. Group 1 included patients with never detected or transient T2ELs (detected at EVAR completion but not after). Group 2 encompassed persistent T2ELs (seen at EVAR completion and again during follow-up) and late T2ELs (detected for the first time at any point during follow-up). Time-to-event analysis was conducted using a time-dependent approach to T2EL status. Primary outcomes included freedom from sac enlargement (SE), aneurysm-related reinterventions, and overall survival. RESULTS: A total of 803 patients met inclusion criteria. Group 1 included 418 patients (52%), of which 85% had no T2ELs and 15% had transient T2ELs. Group 2 had 385 patients; 23% had persistent T2ELs, and 77% developed a new T2EL. Patients in group 1 had a higher prevalence of smoking (88% vs 83%; P < .001), chronic obstructive pulmonary disease (33% vs 25%; P = .008), chronic kidney disease (13% vs 8%; P = .021), and a higher mean Society for Vascular Surgery score (7 vs 6 points; P = .049). No differences were found in aneurysm diameter or morphology. Mean follow-up was 5 years for the entire cohort. In Group 2, 58 patients (15%) underwent T2EL treatment, most commonly transarterial embolization. At 10 years after EVAR, Group 2 was associated with lower freedom from SE (P < .001) and abdominal aortic aneurysm-related reinterventions (P < .001) and comparable overall survival (P = .42). More T1ELs were detected during follow-up in Group 2 (6 [1%] vs 20 [5%]; P = .004), with 15 (75%) of these detected at a median of 3 years after the T2EL. No difference between groups was observed in explant (0.7% vs 2.1%; P = .130) or aneurysm rupture (0.5% vs 1.3%; P = .269) rates. CONCLUSIONS: One-half of patients treated with infrarenal EVAR developed persistent/late T2ELs, which are associated with a higher risk of SE and reinterventions. No difference in overall survival or aneurysm rupture risk was seen at 10 years, based on T2EL status or T2EL intervention. A conservative approach to T2ELs may be appropriate for most patients with absent T1ELs or T3ELs.
引用
- Cifuentes S, Tabiei A, Mendes BC, et al. Implications and late outcomes of type II endoleaks after endovascular aneurysm repair. J Vasc Surg. 2024. PMID: 38663777. doi:10.1016/j.jvs.2024.03.457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。